These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 23292481)

  • 1. Exposure to abatacept or rituximab in the first trimester of pregnancy in three women with autoimmune diseases.
    Ojeda-Uribe M; Afif N; Dahan E; Sparsa L; Haby C; Sibilia J; Ternant D; Ardizzone M
    Clin Rheumatol; 2013 May; 32(5):695-700. PubMed ID: 23292481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-conceptional exposure to rituximab: comment on the article by Ojeda-Uribe et al.
    Gualtierotti R; Ingegnoli F; Meroni PL
    Clin Rheumatol; 2013 May; 32(5):727-8. PubMed ID: 23636791
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment with biologics of pregnant patients with rheumatic diseases.
    Ostensen M; Förger F
    Curr Opin Rheumatol; 2011 May; 23(3):293-8. PubMed ID: 21346578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials.
    Salliot C; Dougados M; Gossec L
    Ann Rheum Dis; 2009 Jan; 68(1):25-32. PubMed ID: 18203761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New therapies for treatment of rheumatoid arthritis.
    Smolen JS; Aletaha D; Koeller M; Weisman MH; Emery P
    Lancet; 2007 Dec; 370(9602):1861-74. PubMed ID: 17570481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of infections in rheumatoid arthritis patients switching from anti-TNF agents to rituximab, abatacept, or another anti-TNF agent, a retrospective administrative claims analysis.
    Johnston SS; Turpcu A; Shi N; Fowler R; Chu BC; Alexander K
    Semin Arthritis Rheum; 2013 Aug; 43(1):39-47. PubMed ID: 23453683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Newer biological agents in the treatment of rheumatoid arthritis: do the benefits outweigh the risks?
    Nurmohamed MT
    Drugs; 2009 Oct; 69(15):2035-43. PubMed ID: 19791825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of RA medications in pregnant patients.
    Østensen M; Förger F
    Nat Rev Rheumatol; 2009 Jul; 5(7):382-90. PubMed ID: 19506586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secondary immune deficiencies associated with biological therapeutics.
    Lee SJ; Yedla P; Kavanaugh A
    Curr Allergy Asthma Rep; 2003 Sep; 3(5):389-95. PubMed ID: 12906774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pregnancy outcomes after maternal exposure to rituximab.
    Chakravarty EF; Murray ER; Kelman A; Farmer P
    Blood; 2011 Feb; 117(5):1499-506. PubMed ID: 21098742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biologic therapies and pregnancy: the story so far.
    Hyrich KL; Verstappen SM
    Rheumatology (Oxford); 2014 Aug; 53(8):1377-85. PubMed ID: 24352337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New therapeutic options in rheumatoid arthritis: a focus on interleukin-6 blockade.
    Furfaro N
    J Infus Nurs; 2011; 34(2):107-15. PubMed ID: 21399456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Perspectives in clinical immunology].
    Rolla G; Ferrero N; Bergia R; Guida G
    Recenti Prog Med; 2006 Dec; 97(12):787-96. PubMed ID: 17252738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fetal outcomes after rituximab exposure in women with autoimmune vasculitis.
    Pendergraft WF; McGrath MM; Murphy AP; Murphy P; Laliberte KA; Greene MF; Niles JL
    Ann Rheum Dis; 2013 Dec; 72(12):2051-3. PubMed ID: 23864238
    [No Abstract]   [Full Text] [Related]  

  • 15. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.
    Brown S; Everett CC; Naraghi K; Davies C; Dawkins B; Hulme C; McCabe C; Pavitt S; Emery P; Sharples L; Buch MH
    Health Technol Assess; 2018 Jun; 22(34):1-280. PubMed ID: 29900829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab in autoimmune hematologic diseases: not just a matter of B cells.
    Stasi R
    Semin Hematol; 2010 Apr; 47(2):170-9. PubMed ID: 20350664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and tolerability of newer biologics in rheumatoid arthritis: best current evidence.
    Siddiqui MA
    Curr Opin Rheumatol; 2007 May; 19(3):308-13. PubMed ID: 17414961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perinatal use and discontinuation of disease-modifying anti-rheumatic drugs and biologics in women with rheumatoid arthritis: a cohort study.
    Rebić N; Sayre EC; Zusman EZ; Amiri N; Baldwin C; De Vera MA
    Rheumatology (Oxford); 2020 Jul; 59(7):1514-1521. PubMed ID: 31628479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy.
    Genovese MC; Schiff M; Luggen M; Becker JC; Aranda R; Teng J; Li T; Schmidely N; Le Bars M; Dougados M
    Ann Rheum Dis; 2008 Apr; 67(4):547-54. PubMed ID: 17921185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induced psoriasis after rituximab therapy for rheumatoid arthritis: a case report and review of the literature.
    Guidelli GM; Fioravanti A; Rubegni P; Feci L
    Rheumatol Int; 2013 Nov; 33(11):2927-30. PubMed ID: 23135613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.